Researchers found a protein that coats the liver is directly correlated with visceral-fat induced diabetes, or type 2 diabetes.

When visceral fat accumulates, the amount of a hormone called adiponectin, decreases. Adiponectin is found in fat cells, and plays a role in glucose regulation and fatty acid metabolism. Researchers found two types of protein on the surface of mouse liver cells. When the proteins and adiponectin interact, blood sugar and neutral fat levels fall, boosting fat-burning functions. However, obese mice with accumulated visceral fat have fewer of these proteins on the surface of their liver cells. When these proteins increased in number, blood sugar levels would decline. The study hypothesizes that if the quantity of adiponectin decreases in obese people, a potential cure for type 2 diabetes may be found by increasing the proteins found on the surface of the liver.

Talk about the power of protein! We've all heard about the leaders in the pack when it comes to dropping pounds - eggs, fish, chicken, soy and whey protein. But this discovery reveals a new way to combat the bulge and reduce your chances of developing type 2 diabetes. Although these new proteins won't find accommodations in your local grocery store - perhaps Big Pharma will have a designer label to sport in the near future. You'd buy it, wouldn't you?

The Juvenile Diabetes Research Foundation announced that they have formed a partnership with MacroGenics. JDRF is providing up to $2 million to fund a clinical trial of a compound called anti-CD3 that has shown promise in slowing the progression of type 1 diabetes.

Anti-CD3 is capable of reducing the autoimmune attack that destroys insulin-producing beta cells. The treatment preserves beta cell function in newly diagnosed patients, and has the potential to decrease insulin requirements, leading to better glucose regulation, and decrease the complications of diabetes. Anti-CD3 blocks the function of CD3 cells - the T cells that destroy islets. The antibodies prevent "activation" of the T cells after they have identified their target, disarming them launching the attack on islets.

Let's hope the peace talks between JDRF, MacroGenics, anti-CD3 and killer Ts result in progressive measures to make the type 1 diabetic body a peaceful place, once and for all.